Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

Publisher： Bentham Science Publishers

E-ISSN： 1875-6417|12|4|403-413

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.12, Iss.4, 2016-10, pp. : 403-413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasinglybeing used for the treatment of type 2 diabetes mellitus, but consideration of benefits and potentialadverse events is required. This review examines the state of glycemic control, weight loss, bloodpressure, and tolerability, as well as the current debate about the safety of GLP-1 RAs, including riskof pancreatitis, pancreatic cancer, and thyroid cancer.lt;/pgt

Related content

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist  

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370 (10)

Adis International

Access to resources Recommend Favorite

Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists

By  

Current Diabetes Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 266-275 (10)

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome

By  

Current Vascular Pharmacology, Vol. 15, Iss. 3, 2017-04 ,pp. : 218-229 (12)

Bentham Science Publishers

Access to resources Recommend Favorite

Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of l-glutamic acid in a type 2 diabetes animal model

By Cancelas Jesús   Villanueva-Peñacrrillo María   Valverde Isabel   Malaisse Willy  

Endocrine Journal, Vol. 16, Iss. 2, 2001-11 ,pp. : 113-116 (4)

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

By Hogan Andrew   Gaoatswe Gadintshware   Lynch Lydia   Corrigan Michelle   Woods Conor   O’Connell Jean   O’Shea Donal  

Diabetologia, Vol. 57, Iss. 4, 2014-04 ,pp. : 781-784 (4)

Springer Publishing Company

Access to resources Recommend Favorite